Latest news
Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.32bn - Eurasia Business NewsEurasia Business News · Mon, 10 Aug 2026 21:36:11 GMT$1.32 Billion for a Molecule: Jazz Pharmaceuticals Bets on Rare-Epilepsy Drug With No Approved Rivals - USA HeraldUSA Herald · Mon, 10 Aug 2026 19:01:18 GMTJazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Mon, 10 Aug 2026 16:17:36 GMTJazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - ReutersReuters · Mon, 10 Aug 2026 15:11:12 GMTJazz bets on epilepsy again by acquiring Actio for $820M upfront - Endpoints NewsEndpoints News · Mon, 10 Aug 2026 13:45:00 GMTJazz Pharmaceuticals (NASDAQ:JAZZ) Given New $276.00 Price Target at JPMorgan Chase & Co. - MarketBeatMarketBeat · Tue, 04 Aug 2026 19:31:56 GMTShould Anticipated Earnings Beat and Employer Award Recognition Require Action From Jazz Pharmaceuticals (JAZZ) Investors? - simplywall.stsimplywall.st · Tue, 28 Jul 2026 17:43:27 GMT